Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Cancer & Metabolism

• Publication date

  2026-02-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s40170-025-00417-yPMID 41634890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Area postrema neurons mediate interleukin-6 function in cancer cachexia

  2024cited by this paper
• Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells.

  2024cited by this paper
• Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan

  2024cited by this paper
• FGF21 induces skeletal muscle atrophy and increases amino acids in female mice: a potential role for glucocorticoids.

  2024cited by this paper
• Depletion of JunB increases adipocyte thermogenic capacity and ameliorates diet-induced insulin resistance

  2024cited by this paper
• Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway

  2023cited by this paper
• The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus

  2023cited by this paper
• Prolonged FOS activity disrupts a global myogenic transcriptional program by altering 3D chromatin architecture in primary muscle progenitor cells

  2022cited by this paper
• GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2–c-Fos–LIF signaling

  2021cited by this paper
• FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K–Akt–mTOR signaling pathway

  2021cited by this paper
• Activation of Activator Protein-1-Fibroblast Growth Factor 21 Signaling Attenuates Cisplatin Hepatotoxicity.

  2021cited by this paper
• Th2 Cytokines Increase the Expression of Fibroblast Growth Factor 21 in the Liver

  2021cited by this paper
• Janus kinase inhibitors suppress cancer cachexia‐associated anorexia and adipose wasting in mice

  2020cited by this paper
• FGF21 promotes non-small cell lung cancer progression by SIRT1/PI3K/AKT signaling.

  2020cited by this paper
• Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy

  2020cited by this paper
• Management of Cancer Cachexia: ASCO Guideline.

  2020cited by this paper
• FGF21 in obesity and cancer: New insights.

  2020cited by this paper
• Fibroblast growth factor 21 controls mitophagy and muscle mass

  2019cited by this paper
• IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia.

  2019cited by this paper
• Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

  2019cited by this paper
• Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer

  2019cited by this paper
• Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

  2019cited by this paper
• Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study

  2019cited by this paper
• Higher serum levels of fibroblast growth factor 21 in old patients with cachexia.

  2019cited by this paper
• Human aging and longevity are characterized by high levels of mitokines.

  2018cited by this paper
• Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals

  2018cited by this paper
• ESPEN expert group recommendations for action against cancer-related malnutrition.

  2017cited by this paper
• Adipose-Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications

  2016cited by this paper
• Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer

  2016cited by this paper
• Mechanisms of metabolic dysfunction in cancer-associated cachexia

  2016cited by this paper
• Inhibition of Osteoarthritis by Adipose‐Derived Stromal Cells Overexpressing Fra‐1 in Mice

  2016cited by this paper
• Cancer cachexia: understanding the molecular basis

  2014cited by this paper
• Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia

  2014cited by this paper
• Fra-2/AP-1 controls adipocyte differentiation and survival by regulating PPARγ and hypoxia

  2014cited by this paper
• Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers.

  2014cited by this paper
• The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway.

  2014cited by this paper
• Stressed Liver and Muscle Call on Adipocytes with FGF21

  2013cited by this paper
• Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice.

  2013cited by this paper
• JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

  2012cited by this paper
• Elevated Fra-1 expression causes severe lipodystrophy

  2011cited by this paper
• Adipose Triglyceride Lipase and Hormone-Sensitive Lipase Are Involved in Fat Loss in JunB-Deficient Mice

  2011cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production

  2010cited by this paper
• FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

  2009cited by this paper
• Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis.

  2009cited by this paper
• Increased energy expenditure and insulin sensitivity in the high bone mass DeltaFosB transgenic mice.

  2009cited by this paper
• Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States

  2008cited by this paper
• JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia.

  2008cited by this paper
• The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

  2007cited by this paper
• Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.

  2007cited by this paper
• Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity

  2007cited by this paper
• The AP‐1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia

  2006cited by this paper
• Forced expression of hepatocyte‐specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis

  2006cited by this paper
• Essential role of RSK2 in c-Fos-dependent osteosarcoma development.

  2005cited by this paper
• FGF-21 as a novel metabolic regulator.

  2005cited by this paper
• Forebrain patterns of c‐Fos and FosB induction during cancer‐associated anorexia–cachexia in rat

  2005cited by this paper
• ΔFosB Induces Osteosclerosis and Decreases Adipogenesis by Two Independent Cell-Autonomous Mechanisms

  2004cited by this paper
• The Fos‐related antigen Fra‐1 is an activator of bone matrix formation

  2004cited by this paper
• ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome.

  2004cited by this paper
• AP-1: a double-edged sword in tumorigenesis

  2003cited by this paper
• JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms

  2002cited by this paper
• Promoter Specificity and Biological Activity of Tethered AP-1 Dimers

  2002cited by this paper
• Overexpression of ΔFosB transcription factor(s) increases bone formation and inhibits adipogenesis

  2000cited by this paper
• Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation

  2000cited by this paper
• Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1

  2000cited by this paper
• Induction of bone tumors in transgenic mice by C-FOS depends on the presence of a retroviral long terminal repeat.

  1998cited by this paper
• A New Method to Isolate Large Numbers of Rabbit Osteoclasts and Osteoclast‐like Cells: Application to the Characterization of Serum Response Element Binding Proteins During Osteoclast Differentiation

  1998cited by this paper
• C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression

  1998cited by this paper
• Osteoblasts are target cells for transformation in c-fos transgenic mice

  1993cited by this paper
• The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas.

  1990cited by this paper
• c-fos expression induces bone tumors in transgenic mice.

  1989cited by this paper
• Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro.

  1988cited by this paper
• FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA

  1982cited by this paper

• No citing papers are available for this paper.